1751-7176/asset/olbannerleft.gif?v=1&s=e1329e97d266c876232b9dd119e3a8eb68b7184c)
1751-7176/asset/olbannerright.gif?v=1&s=41f410e8e629a1248a3cd67bdebc1514226c9ea8)
The Effects of an Olmesartan Medoxomil–Based Treatment Algorithm on 24-Hour Blood Pressure Levels in Elderly Patients Aged 65 and Older
Article first published online: 26 JUN 2009
DOI: 10.1111/j.1751-7176.2009.00147.x
© 2009 Wiley Periodicals, Inc.
Additional Information
How to Cite
Kereiakes, D. J., Neutel, J., Stoakes, K. A., Waverczak, W. F., Xu, J., Shojaee, A. and Dubiel, R. (2009), The Effects of an Olmesartan Medoxomil–Based Treatment Algorithm on 24-Hour Blood Pressure Levels in Elderly Patients Aged 65 and Older. The Journal of Clinical Hypertension, 11: 411–421. doi: 10.1111/j.1751-7176.2009.00147.x
Publication History
- Issue published online: 6 AUG 2009
- Article first published online: 26 JUN 2009
- Manuscript received April 30, 2009; revised May 29, 2009; accepted June 1, 2009
- Abstract
- Article
- References
- Cited By
This study examined the effect of olmesartan medoxomil (OM) ± hydrochlorothiazide (HCTZ) on mean 24-hour ambulatory blood pressure, mean seated cuff (Se) blood pressure (BP), and SeBP goal achievement in elderly (65 years and older) patients with hypertension. After a 2- to 3-week placebo run-in period, patients received OM 20 mg, up-titrated to OM 40 mg, and then added HCTZ 12.5 mg to 25 mg in a stepwise manner at 3-week intervals if SeBP remained ≥120/70 mm Hg. The primary end point was change from baseline in mean 24-hour ambulatory systolic BP. At study end, mean 24-hour ambulatory BP had decreased by 25.7/12.3 mm Hg (n=150) and mean SeBP by 25.4/10.5 mm Hg (n=176; all P<.00001 vs baseline). Drug-related treatment-emergent adverse events, most commonly dizziness (3.4%), hypotension (2.2%), and headache (1.1%), were observed in 11.8% of patients. An OM-based treatment algorithm effectively lowers BP in an elderly patient population throughout the 24-hour dosing interval without compromising tolerability.